72761-60-5

Usage

Uses

Used in Pharmaceutical Industry:
9-Azabicyclo(3.3.1)nonan-3-one Hydrochloride is used as a key intermediate in the development of new drugs targeting the central nervous system. Its structural similarity to certain neurotransmitters makes it a promising candidate for the creation of medications that can modulate neurotransmission and treat neurological disorders.
Used in Chemical Research:
9-Azabicyclo(3.3.1)nonan-3-one Hydrochloride serves as a valuable building block in the synthesis of complex organic molecules. Its unique bicyclic structure with a nitrogen atom allows for the formation of various functional groups and the development of novel compounds with potential applications in different fields.
Used as a Reagent in Organic Chemistry Reactions:
9-Azabicyclo(3.3.1)nonan-3-one Hydrochloride is utilized as a reagent in various organic chemistry reactions, enabling the preparation of complex molecules with specific properties. Its versatility and reactivity make it an essential component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.

InChI:InChI=1/C8H13NO.ClH/c10-8-4-6-2-1-3-7(5-8)9-6;/h6-7,9H,1-5H2;1H

Upstream product

• 1336-21-6 ammonium hydroxide 
• 149381-95-3 9-(2,2,2-trichlorocarbethoxy)-9-azabicyclo[3.3.1]nonan-3-one 
• 552-70-5 pseudopelletierine 
• 512822-27-4 tert-butyl 3-oxo-9-azabicyclo[3.3.1]nonane-9-carboxylate 

Downstream Products

• 926658-81-3 9-[(4-chlorophenyl)sulfonyl]-9-azabicyclo[3.3.1]nonan-3-one 
• 512822-27-4 tert-butyl 3-oxo-9-azabicyclo[3.3.1]nonane-9-carboxylate 
• 934180-37-7 tert-butyl (1R,3r,5S)-3-hydroxy-9-azabicyclo[3.3.1]nonane-9-carboxylate 
• 180406-57-9 N-p-tolylsulfonyl-9-azabicyclo<3.3.1>nonan-3-one 
• 180406-53-5 methyl (2R,6S)-2-<(E)-1-propenyl>-N-(p-tolylsulfonyl)piperidine-6-ethanoate 
• 225089-42-9 methyl (2S,6R)-2-<(E)-1-propenyl>-N-(p-tolylsulfonyl)piperidine-6-ethanoate 
• 180580-54-5 (1S,5R)-N-(p-tolylsulfonyl)-3-(trimethylsilyloxy)-9-azabicyclo<3.3.1>non-2-ene 
• 180406-45-5 (1R,5S)-N-(p-tolylsulfonyl)-3-(trimethylsilyloxy)-9-azabicyclo<3.3.1>non-2-ene 
• 180406-54-6 (2R,6S)-6-formylmethyl-2-<(E)-1-propenyl>-N-(p-tolylsulfonyl)piperidine 
• 225089-43-0 (2S,6R)-6-formylmethyl-2-<(E)-1-propenyl>-N-(p-tolylsulfonyl)piperidine 
• 501-02-0 (-)-pinidine 

Relevant academic research and scientific papers

Scaffold hopping approach towards various AFQ-056 analogs as potent metabotropic glutamate receptor 5 negative allosteric modulators

The metabotropic glutamate receptor subtype 5 has evolved into a promising target for the treatment of various diseases of the central nervous system, such as Fragile X and l-DOPA induced dyskinesia. One of the most advanced clinical compound is Novartis'

NOVEL 9-AZA-BICYCLO[3.3.1]NON-3-YLOXY CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS

This invention relates to novel 9-aza-bicyclo[3.3.1]non-3-yloxy chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

BRIDGED N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE

The invention provides N-cyclic sulfonamido compounds and salts of Formula (I): wherein A is as described in the specification and R1 and R2combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula (I) are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula (I).

5,6,7,8,9,10-HEXAHYDRO-7,10-IMINOCYCLOHEPT[B]INDOLE,-6,7,8,9,10-HEXAHYDRO-7,11-IMINO-5H-CYCLOOCT[B]INDOLE AND SUBSTITUTED DERIVATIVES

5,6,7,8,9,10-Hexahydro-7,10-iminocyclohept[b]indole, 6,7,8,9, 10,11-hexahydro-7,11-imino-5H-cyclooct[b]indole and substituted derivatives are effective in the treatment of psychoses with limited liability to produce concomitant adverse extrapyramidal symp